{
    "ticker": "GANX",
    "name": "Gain Therapeutics, Inc.",
    "description": "Gain Therapeutics, Inc. is a biotechnology company focused on advancing the treatment of neurodegenerative diseases through its proprietary drug discovery platform. Founded in 2019, Gain Therapeutics is dedicated to developing therapies that target the underlying causes of diseases such as Alzheimer\u2019s, Parkinson\u2019s, and other related disorders. The company utilizes a unique approach known as 'targeted protein modulation' to enhance the function of misfolded proteins, offering hope for patients suffering from these debilitating conditions. Gain Therapeutics has made significant strides in its research, particularly with its lead candidate, GT-022, which is aimed at treating Gaucher disease, a genetic disorder that can lead to severe neurological complications. With a team of experienced scientists and industry veterans, Gain Therapeutics is committed to innovation and excellence in drug development. The company is also focused on building strategic partnerships to accelerate the advancement of its therapeutic candidates through clinical trials, ultimately aiming to bring transformative treatments to market. Gain Therapeutics envisions a future where patients with neurodegenerative diseases can lead healthier and more fulfilling lives through effective and targeted therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2019",
    "website": "https://www.gaintherapeutics.com",
    "ceo": "Alfredo J. Qui\u00f1ones-Hinojosa",
    "social_media": {
        "twitter": "https://twitter.com/gaintherapeutics",
        "linkedin": "https://www.linkedin.com/company/gain-therapeutics"
    },
    "investor_relations": "https://ir.gaintherapeutics.com",
    "key_executives": [
        {
            "name": "Alfredo J. Qui\u00f1ones-Hinojosa",
            "position": "CEO"
        },
        {
            "name": "Jorge L. M. Ferreira",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "GT-022"
            ]
        }
    ],
    "seo": {
        "meta_title": "Gain Therapeutics, Inc. | Innovative Treatments for Neurodegenerative Diseases",
        "meta_description": "Gain Therapeutics, Inc. is a biotechnology company dedicated to developing therapies for neurodegenerative diseases using targeted protein modulation.",
        "keywords": [
            "Gain Therapeutics",
            "Neurodegenerative Diseases",
            "Biotechnology",
            "Pharmaceuticals",
            "GT-022",
            "Gaucher Disease"
        ]
    },
    "faq": [
        {
            "question": "What is Gain Therapeutics known for?",
            "answer": "Gain Therapeutics is known for its innovative approach to developing therapies for neurodegenerative diseases."
        },
        {
            "question": "Who is the CEO of Gain Therapeutics?",
            "answer": "Alfredo J. Qui\u00f1ones-Hinojosa is the CEO of Gain Therapeutics, Inc."
        },
        {
            "question": "Where is Gain Therapeutics headquartered?",
            "answer": "Gain Therapeutics is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are Gain Therapeutics' main products?",
            "answer": "Gain Therapeutics' main product is GT-022, a therapeutic candidate for Gaucher disease."
        },
        {
            "question": "When was Gain Therapeutics founded?",
            "answer": "Gain Therapeutics was founded in 2019."
        }
    ],
    "competitors": [
        "ACAD",
        "BIIB",
        "SAGE",
        "SGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}